Cargando…

A prospective study exploring the predictors of response to benralizumab in patients with refractory bronchial asthma

OBJECTIVE: This study aimed to evaluate the predictors of response to benralizumab therapy in patients with refractory bronchial asthma. METHODS: After 16 weeks of benralizumab therapy, 32 patients with refractory bronchial asthma were assigned to two groups based on the response to treatment as ind...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hirose, Masahiro, Kuwabara, Kazunobu, Kondo, Rieko, Horiguchi, Takahiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fujita Medical Society 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874918/ https://www.ncbi.nlm.nih.gov/pubmed/35233342 http://dx.doi.org/10.20407/fmj.2020-024

Ejemplares similares

Sex differences in use of inhalants by elderly patients with asthma
por: Hirose, Masahiro, et al.
Publicado: (2015)

Long-term clinical effects of an inhaler guidance DVD in patients with bronchial asthma
por: Yoshida, Takazumi, et al.
Publicado: (2021)

Use of Assist Devices to Actuate Pressurized Metered-Dose Inhalers in Elderly Patients with Asthma
por: Hirose, Masahiro, et al.
Publicado: (2021)

Evaluation of the pneumococcal urinary antigen test (PUT): a retrospective study
por: Yokoi, Tatsuyoshi, et al.
Publicado: (2021)

Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma
por: Gómez-Bastero Fernández, Ana, et al.
Publicado: (2022)

Asthma phenotypes
por: Hirose, Masahiro, et al.
Publicado: (2017)

Mepolizumab asthma treatment failure due to refractory airway eosinophilia, which responded to benralizumab
por: Cook, Alistair, et al.
Publicado: (2021)

Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
por: Noorduyn, Stephen G., et al.
Publicado: (2021)

A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment
por: Davison, John, et al.
Publicado: (2021)

Identification of distinct phenotypes related to benralizumab responsiveness in patients with severe eosinophilic asthma
por: Yamada, Hideyasu, et al.
Publicado: (2021)

The clinical profile of benralizumab in the management of severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016)

Childhood-onset severe hypereosinophilic asthma: efficacy of benralizumab
por: Just, Jocelyne, et al.
Publicado: (2020)

Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma
por: Yan, Li, et al.
Publicado: (2019)

Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma
por: Wang, B, et al.
Publicado: (2017)

Postbronchodilator lung function improvements with benralizumab for patients with severe asthma
por: Mathur, Sameer K., et al.
Publicado: (2020)

Real-life cost-effectiveness of benralizumab in patients with severe asthma
por: Padilla-Galo, A., et al.
Publicado: (2021)

Rapid and remarkable effectiveness of benralizumab for treating severe bronchial asthma with intractable eosinophilic rhinosinusitis and eosinophilic otitis media: A case report
por: Shimizu, Hideyasu, et al.
Publicado: (2020)

Impact of initial empirical antimicrobial choice and cause of in-hospital death in patients with nursing and healthcare-associated pneumonia (NHCAP): A retrospective study
por: Kato, Kenichi, et al.
Publicado: (2022)

Effectiveness and safety of benralizumab for severe asthma in clinical practice (J-BEST): a prospective study
por: Izumo, Takehiro, et al.
Publicado: (2020)

Benralizumab: a unique IL-5 inhibitor for severe asthma
por: Tan, Laren D, et al.
Publicado: (2016)

Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma
por: Moran, Angela M., et al.
Publicado: (2020)

Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial
por: Menzies-Gow, Andrew, et al.
Publicado: (2019)

Real world effectiveness of benralizumab on respiratory function and asthma control
por: Menzella, Francesco, et al.
Publicado: (2021)

Effect of benralizumab in a patient with uncontrolled severe eosinophilic asthma and comorbid chronic rhinosinusitis with nasal polyps refractory to mepolizumab treatment
por: Mansur, Adel H.
Publicado: (2021)

Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma
por: Bleecker, Eugene R., et al.
Publicado: (2018)

Efficacy and Safety of Benralizumab for Korean Patients With Severe, Uncontrolled Eosinophilic Asthma
por: Park, Hae-Sim, et al.
Publicado: (2019)

Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic Asthma
por: Chia, Yen Lin, et al.
Publicado: (2019)

Serum microRNAs as Tool to Predict Early Response to Benralizumab in Severe Eosinophilic Asthma
por: Cañas, José A., et al.
Publicado: (2021)

Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab
por: Menzella, Francesco, et al.
Publicado: (2021)

Benralizumab in the treatment of severe asthma: design, development and potential place in therapy
por: Pelaia, Corrado, et al.
Publicado: (2018)

Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab
por: Jackson, David J., et al.
Publicado: (2020)

Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma
por: FitzGerald, J Mark, et al.
Publicado: (2019)

Molecular Targets for Biological Therapies of Severe Asthma: Focus on Benralizumab and Tezepelumab
por: Cheng, Shih-Lung
Publicado: (2021)

Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthma
por: Chan, Rory, et al.
Publicado: (2023)

Medium-term repeatability for airwave oscillometry in patients with severe asthma taking benralizumab
por: Chan, Rory, et al.
Publicado: (2023)

Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience
por: Scioscia, Giulia, et al.
Publicado: (2023)

Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub‐phenotypes of response identified by cluster analysis
por: Di Bona, Danilo, et al.
Publicado: (2021)

Eosinophilic cystitis refractory to steroids successfully treated with benralizumab: A case report
por: Konstantinou, George N., et al.
Publicado: (2023)

Seasonal variation in the prevalence of Gram-negative bacilli in sputum and urine specimens from outpatients and inpatients
por: Kito, Yusuke, et al.
Publicado: (2022)

Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study)
por: Martínez-Moragón, Eva, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rlu5rmn9c887gn3vjggjb84ip2